Top-line results from a pivotal Phase III clinical trial of CXA 201 (ceftolozane/tazobactam), from Cubist Pharma, in complicated Intra-Abdominal Infections...
Zerbaxa (ceftolozane / tazobactam) from Merck Inc., received a positive opinion from the CHMP for the treatment of complicated intra-abdominal...
Cubist Pharmaceuticals, Inc. has announced that it has submitted on 21 April 2014, a New Drug Application (NDA) to the...
Cubist Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has accepted for review the Company's Marketing Authorization Application (MAA)...
Cubist Pharmaceuticals, Inc. announced positive top-line results from the Company�s pivotal Phase III clinical trial of its antibiotic candidate ceftolozane/tazobactam...
Merck Inc. has announced that The Lancet and Clinical Infectious Diseases have published online the results from the pivotal Phase...
Zerbaxa is indicated for the treatment of the following infections in adults (see section 5.1): - Complicated intra-abdominal infections (see section 4.4); - Acute pyelonephritis; - Complicated urinary tract infections (see section 4.4); - Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Cubist Pharmaceuticals, Inc. has announced the first detailed results from positive pivotal Phase III clinical trials of its antibiotic candidate...
Cubist Pharmaceuticals, Inc. announced that the FDA approved Zerbaxa (ceftolozane/tazobactam) for the treatment of adults with Complicated Urinary Tract Infections...